Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at AED 300.9B, ahead of Gilead Sciences (AED 133.7B) and Biogen (AED 41.1B). Figures as of 18 Nov 2026, 14:08 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenAED 300.9B
- Median
- AED 2.6B
- Combined market value
- AED 3.12T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | AED 300.9B | AED 909.7B | AED 1,681.75 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | AED 133.7B | AED 775.6B | AED 625.28 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | AED 41.1B | AED 136.1B | AED 921.03 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | AED 13.5B | AED 307.3B | AED 759.47 | 3.93% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | AED 11.3B | AED 77.3B | AED 311.65 | 0.47% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | AED 9.2B | AED 37.7B | AED 182.71 | 0.12% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | AED 9.1B | AED 40.2B | AED 352.45 | 0.55% down | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | AED 5.1B | AED 61.7B | AED 609.34 | 0.37% up | 20% up | ||
| 9 | argenxARGX · Health Care | AED 5B | AED 218.8B | AED 3,479.77 | 0.36% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | AED 3.7B | AED 24.5B | AED 22.99 | 4.68% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | AED 3.1B | AED 38.1B | AED 595.61 | 0.37% down | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | AED 2.7B | AED 129.2B | AED 597.48 | 2.50% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | AED 2.5B | AED 61.4B | AED 251.57 | 2.09% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | AED 1.8B | AED 41.9B | AED 266.73 | 0.22% down | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | AED 1.3B | AED 14.3B | AED 147.45 | 0.54% down | 21% down | ||
| 16 | VaxcytePCVX · Health Care | AED 1.2B | AED 34.5B | AED 218.15 | 3.59% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | AED 1.1B | AED 16.9B | AED 104.63 | 2.22% up | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | AED 713M | AED 23.2B | AED 355.50 | 3.90% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | AED 620.3M | AED 28B | AED 411.32 | 6.63% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | AED 599.2M | AED 38.1B | AED 446.28 | 3.44% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | AED 583.1M | AED 20.2B | AED 165.56 | 1.21% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | AED 419.5M | AED 32.5B | AED 1,096.42 | 0.22% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | AED 383.5M | AED 25.2B | AED 121.96 | 0.21% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | AED 143.2M | AED 25.9B | AED 289.91 | 6.89% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6725 AED).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (AED 300.9B), Gilead Sciences (AED 133.7B) and Biogen (AED 41.1B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 14:08 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of AED 3.12T as of 18 Nov 2026, 14:08 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.